RNS Number : 9640U
Intosol Holdings PLC
03 August 2020
INTOSOL Holdings Plc ('INTOSOL' or the 'Company')
Suspension of Listing Amended
INTOSOL Holdings Plc. ('INTOSOL' or the 'Company'), announces the following:
The Company has
requested
under Listing Rule LR 5.3.1 a suspension of the listing of the common shares listed on the Standard Market of the London Stock Exchange from 7.30 AM August 3, 2020.
1. Name and registered office address of the Issuer:
Intosol Holding Plc.
CIN: L29120UP1987PLC091016
Registered office address:
27-28 Eastcastle Street, London, United Kingdom, W1W 8DH
2. Securities subject to suspension:
The Company's common voting shares are trading on the Standard Segment of the London Stock Exchange
. The
common voting shares
are currently traded on the SM of the LSE as per the details given hereunder:
Symbol: INTO
ISIN: GB00BFYY4Y44
3. Reasons for suspension: of listing and trading:
The Company is unable to meet the filing deadline of its audited financial statements year ending January 31, 2020 (the "2020 FS") and expects to file within the net 10 working days. The current
outbreak of the novel strain of coronavirus, specifically identified as "COVID-19", has had a material impact on completing in a timely way the audited 2020 FS.
4. Schedule of suspension of listing and trading:
The suspension of listing and trading of
common voting shares
on the LSE shall be effective from
7.30 AM August 3, 202
0
.
The Company expects to file the 2020 FS in the near future and seek recommencement to trading subject to regulatory approval.
ENQUIRIES
Rainer Spekowius Chairman
Email: [email protected]
INTOSOL Holdings PLC
INTOSOL Holdings PLC is a London listed international luxury travel company that merges private travel design with hotel management and property ownership to provide bespoke, high-end global travel experiences across the world.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
[email protected] or visit
www.rns.com.
END
SUSUPUCGRUPUGPW